Signatera Genome ultra-sensitive ctDNA blood test

DEVICE4 trials

Sponsors

Yale University, Natera, Inc.

Conditions

Advanced Solid TumorsAdvanced Solid Tumors CancerAmpullary AdenocarcinomaCRCDMMR Colorectal CancerDuodenal AdenocarcinomaEndometrial CancerEsophageal Adenocarcinoma

Phase 2

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

RecruitingNCT07282912

Yale UniversityAmpullary Adenocarcinoma, Duodenal Adenocarcinoma, Esophageal Adenocarcinoma +6

Start: 2026-06-02End: 2028-06-01Target: 54Updated: 2026-09-08

Unknown Phase

Signatera Assessment in Early-Stage Endometrial Cancer

Not yet recruitingNCT07339384

Natera, Inc.Endometrial Cancer

Start: 2026-10-01End: 2034-10-01Target: 1010Updated: 2026-06-17

Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer

Not yet recruitingNCT07565857

Natera, Inc.Gastric-Esophageal Cancer

Start: 2026-09-01End: 2034-09-01Target: 1000Updated: 2026-05-04

A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

Not yet recruitingNCT07689812

Natera, Inc.Advanced Solid Tumors, Advanced Solid Tumors Cancer, CRC +12

Start: 2026-12-01End: 2034-03-01Target: 920Updated: 2026-08-04